8-K: Lifeloc Technologies Reports Q2 2026 Results, Revenue Up 10%

Lifeloc Technologies announced second quarter 2026 results, showing a 10% increase in net revenue to $2.445 million and improved gross margins, though the company reported a net loss of $134,000.

Summary

• Lifeloc Technologies reported second quarter 2026 net revenue of $2.445 million, a 10% increase compared to $2.219 million in the second quarter of 2025.
• The company experienced a net loss of $134,000 ($0.05 per diluted share) for Q2 2026, an improvement from a net loss of $394,000 ($0.14 per diluted share) in Q2 2025.
• For the first six months of 2026, net revenues were $4.739 million with a net loss of $287,000 ($0.10 per diluted share), compared to $4.496 million and a net loss of $686,000 ($0.25 per diluted share) in the same period of 2025.
• Gross margin increased to 45% in Q2 2026 from 42% in Q2 2025, and for the first six months, it rose to 44% from 41% year-over-year, attributed to price increases and a favorable product mix.
• Research and development investment remained high at $560,000 for the quarter, primarily for the SpinDetect analyzer development.
• Lifeloc secured $500,000 in financing through a loan from its Chairman of the Board, who also serves as CFO.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a cautiously optimistic report, with revenue growth and improved gross margins offset by continued net losses and significant R&D investment for future products.

Positives

• Net revenue increased by 10% to $2.445 million in the second quarter of 2026 compared to the prior year's quarter.
• Gross margin improved to 45% in Q2 2026 from 42% in Q2 2025, and to 44% for the first six months of 2026 from 41% in the prior year.
• Net loss narrowed significantly to $134,000 in Q2 2026 from $394,000 in Q2 2025.
• Six-month net loss also narrowed to $287,000 from $686,000 in the comparable period of 2025.
• The company has secured $500,000 in financing from its Chairman of the Board on favorable terms.
• New L-series alcohol detection devices are meeting modern standards and are expected to be incremental to existing FC-series sales.

Negatives

• The company reported a net loss of $134,000 for the second quarter of 2026.
• The company reported a net loss of $287,000 for the first six months of 2026.
• Research and development investment remains high at $560,000 for the quarter, contributing to the net loss.
• The company has a significant accumulated deficit of $2,117,579 as of June 30, 2026.

Risks

• The SpinDetect analyzer development requires significant ongoing R&D investment, and its commercial launch is targeted for Q1 2027.
• The company's loan from its Chairman of the Board is secured by all company assets.
• Forward-looking statements involve substantial risks and uncertainties that may cause actual results to differ materially from those indicated.

Future Outlook

The company is targeting a limited commercial launch of its SpinDetect oral-fluid analyzer in Q1 2027. Subsequent releases are expected to expand to additional drug panels, blood and breath samples, and other applications like food pathogen detection. The L-series alcohol detection devices are expected to drive market penetration.

Management Comments

• "It is great to see assays performed with all the chemistry occurring on the disk. With our second dispensing robot scheduled for delivery later this month, we are moving closer to production," commented Dr. Wayne Willkomm, President and CEO.
• Management believes the core alcohol detection product line-up is strong, with newer L-series devices meeting modern standards and expected to be incremental to FC-series sales.
• Management views the SpinDetect Centrifugal Drug Analyzer as the most significant long-term opportunity.

Industry Context

StockSavvy.ai notes that Lifeloc Technologies operates in the critical but competitive field of alcohol and drug detection devices. The company's focus on developing advanced technologies like the SpinDetect analyzer aligns with industry trends towards more rapid, on-site, and quantitative testing solutions, particularly for drugs. The reported revenue growth and improved margins are positive signs in this sector, though continued investment in new product development is essential for long-term success.

Related Party Transactions

• The company closed on $500,000 of financing through a loan from its Chairman of the Board, who also serves as its Chief Financial Officer. The loan terms include 10.5% interest, interest-only payments in 2026, a 5-year repayment period, and is secured by all company assets.

Stakeholder Impact

• Shareholders: The improved financial performance (revenue growth, reduced loss) is positive, but continued R&D investment and net losses may temper immediate returns. The loan from the Chairman provides necessary capital but is secured by all assets.
• Employees: Continued investment in R&D and new product development (SpinDetect) suggests a commitment to future growth, potentially leading to job security and opportunities.
• Creditors: The secured loan from the Chairman provides capital, but the fact that it is secured by all assets could impact other creditors in a liquidation scenario.

Next Steps

• Initiate beta testing of the oral-fluid SpinDetect analyzer.
• Target a limited commercial launch of the SpinDetect analyzer in Q1 2027.
• Continue development of SpinDetect for additional drug panels and other sample types (blood, breath).
• Continue sales and market penetration of L-series and FC-series alcohol detection devices.

Key Dates

Recommendation

The company shows positive revenue growth and improving margins, indicating operational progress. However, the continued net losses, significant R&D spend for a product with a Q1 2027 launch, and the debt secured by all assets warrant a cautious approach. Investors should monitor the progress of the SpinDetect platform and its path to profitability.

Keywords

breath alcohol testing, drug testing devices, SpinDetect, revenue growth, gross margin, net loss, financial results, Q2 2026